Roche has announced a $50 billion investment over five years to enhance its manufacturing capabilities in the U.S., joining other major drugmakers like Johnson & Johnson and Eli Lilly in expanding production amid concerns over tariffs and global trade disruptions. This investment aims to create new facilities for obesity medications and gene therapies while also upgrading existing plants across several states, generating approximately 12,000 jobs. Roche’s CEO emphasized the company’s long-term commitment to U.S. innovation and job creation, as they navigate potential new tariffs from the Trump administration.

Source: https://www.supplychaindive.com/news/roche-50-billion-us-drug-diagnostics-manufacturing/746111/